)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Wave Life Sciences
Wave Life Sciences (WVE) investor relations material
Wave Life Sciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic vision and innovation
Focus on unlocking the potential of RNA medicines, leveraging proprietary chemistry and deep genetic insights for rapid translation from genetic insights to clinical candidates.
In-house GMP manufacturing and strong IP position support innovation, scalability, and swift clinical advancement.
Well-capitalized with $602 million in cash, funding operations into Q3 2028.
Innovations in siRNA chemistry yield 10-15x improvement in AGO2 loading, enhancing potency and durability.
Bifunctional oligonucleotide constructs enable simultaneous RNA editing and silencing, expanding therapeutic reach.
Clinical and preclinical program highlights
WVE-007 (INHBE) for obesity shows durable fat loss and muscle preservation, with potential for once or twice-yearly dosing.
INLIGHT studies demonstrate significant reductions in visceral and total fat, with lean mass preserved.
Preclinical data support synergistic use of WVE-007 with GLP-1s and prevention of weight regain post-incretin therapy.
RNA editing programs target Alpha-1 antitrypsin deficiency (AATD) and PNPLA3 for liver disease, with WVE-006 restoring wild-type AAT protein and WVE-008 targeting over nine million patients.
Extrahepatic programs deliver to adipose, muscle, and CNS, with bifunctional oligonucleotides in development.
Near-term milestones and development plans
Multiple obesity data readouts expected in 2024, including higher dose and longer-term results.
Accelerating WVE-007 development with higher dose and longer follow-up data, and initiating Phase 2a multidose trial in 1H 2026.
WVE-006 to deliver 400 mg multidose data in 1Q 2026 and 600 mg cohort data later in 2026.
WVE-008 CTA filing expected in 2026, aiming to address PNPLA3-driven liver disease.
NDA submission for WVE-N531 (DMD) and IND for WVE-003 (HD) planned for 2026.
WVE-007's durability vs. other Inhibin E programs
WVE-007's role in obesity maintenance therapy
Why edit PNPLA3 versus silencing?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Wave Life Sciences earnings date
Q4 20254 Mar, 2026
Wave Life Sciences
Next Wave Life Sciences earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Wave Life Sciences Ltd. (WVE) is a biotechnology company leveraging its proprietary RNA medicines platform, PRISM, to develop transformative treatments for a range of genetic diseases. This platform enables the design, optimization, and production of novel stereopure oligonucleotides, aimed at correcting disease-causing mutations, modulating protein activity, and restoring functional protein production or reducing disease-promoting RNAs or proteins. Wave's diverse pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical program for obesity, among others. Their approach includes multiple RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, showcasing their broad capabilities in addressing complex disease biology. The company is headquartered in Singapore, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage